Fabry Disease Screening in ESRD Patients in West of France

Fabry Disease Prevalence in End-stage Renal Disease (ESRD) Patients on Dialysis or Transplant in West of France

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02719249

Acronym

SNOUFY

Enrollment

500

Registered

2016-03-25

Start date

2016-01-31

Completion date

2018-06-30

Last updated

2018-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESRD

Keywords

ESRD, Fabry disease

Brief summary

Screening of Fabry disease in end-stage renal disease (ESRD) patients on dialysis or transplant in west of France.

Detailed description

Detection of Fabry disease is done by dried blood spot test, in dialyzed and transplanted men, who reached ESRD for vascular or unknown disease and were not previously screened.

Interventions

OTHERDried blood spot test

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Men less than 70 years old * ESRD treated by dialysis or kidney graft in one of the 4 following regions : Bretagne, Centre, Pays de la Loire and Poitou-Charentes * For unknown nephropathy OR vascular nephropathy and/or diabetic nephropathy unproved by biopsy * Agreeing freely to participate in the study

Exclusion criteria

* Men less than 18 years old * Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.

Design outcomes

Primary

Measure	Time frame
To detect Fabry disease by dried blood spot test, in dialyzed and transplanted men, who reached ESRD for vascular or unknown disease and were not previously screened	1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026